Delivering the Added Dimension in Scale-up - Webinar by Jubilant Biosys

Jubilant Biosys will be conducting a webinar to discuss the transformation needed in decision-making, assessment, and bringing in scale-up expertise earlier than typically done through PR&D scientists.
By: Jubilant Biosys
 
 
Spread the Word
Listed Under

Tag:
Drug discovery services

Industry:
Biotech

Location:
Paris - Paris - France

PARIS - June 30, 2020 - PRLog -- At the end of your discovery process and having selected your lead candidate, you now need pivotal TOX batches and GMP phase 1 material for IND submission. Medicinal chemistry is done at a low gram scale and the focus is finding the right molecular architecture, whereas the scale-up phase requires kilo range amounts often a 100X factor up from MedChem.

Time is of the essence and as regulatory requirements are still forgiving in this early phase the temptation is to try and brute-force the 'MedChem' route. This can work with moderately complex routes but in recent years the majority of the candidates are the result of lengthy and complex synthetic schemes.

In addition, we offer a platform for all attendants to share their best practices and experience so IND submission can be accelerated with better chemistry and technology decisions including the right focus on process impurities in human trials.

Common assumptions seen in practices:

·         Why lose time on a new route?  "We need it fast, let us make it this way"

·         "My route is better"

·         Medicinal chemists have been seen to be satisfied with their route in 70 % of the cases (what is the source of this statement?)

Foreseeable Engineering & Technology aspect:

·         Need for Column chromatography

·         Use of SFC – rather an avoidance of it

·         Isolation issues and other purification aspects

Foreseeable regulatory aspects:

·         The solvents & catalysts being used

·         Impurities

·         Use of cleanroom

Applicability of technology:

·         Use of flow/photochemistry

Analytical aspects:

·         Level of details in the qualification of API – what assay level is best?

·         Techniques needed for the qualification of material

·         Setting up the limits for impurities, metals, OVI, moisture

·         Solid-state characterization – when to do it?

Final recommendation and discussion

Webinar Speakers:

1.     Marcel Velterop

President – Drug Discovery Services & CDMO – Jubilant Biosys Limited

2.     Dr. Vikas Shirsath
Senior Vice President – Global Operations – Jubilant Biosys Limited

3.     Purushotham Vandanapu
Director – Scale-up Chemistry Operations – Jubilant Biosys Limited

About Jubilant Biosys Limited:

Jubilant Biosys, a subsidiary of Jubilant Life Sciences Limited, is a Contract Research Organization with its R&D centers in India and business offices in Asia and North America. Jubilant Biosys specializes in comprehensive drug discovery services for the global pharmaceutical industry.

With having strong clinical development, Jubilant Biosys has risen as a fully integrated contract research organization in India (https://www.jubilantbiosys.com/) and headquartered at Bengaluru with end-to-end solutions.

For more info: www.jubilantbiosys.com

Contact
Jubilant Biosys
***@jubilantbiosys.com
End
Email:***@jubilantbiosys.com
Tags:Drug discovery services
Industry:Biotech
Location:Paris - Paris - France
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Dignitas Digital PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share